anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine composition for treating cerebral hemorrhage. The composition is prepared from allium victorialis, trapa incise root, fennelflower, sculellaria barbata, fennel root, meliosma rigida, China root greenbrier leaf, pyropolyporus formentarius teng, radix astragali preparata, salviae miltiorrhizae, longstamen onion bulb, broadleaf holly leaf, caulis et folium plucheae, common fenugreek seed, lotus plumule, hispid arthraxon, oyster plant leaf, woolly-fruited glochidion root, thunbergia fragrans and herba andrographitid. The traditional Chinese medicine composition is especially used for treating cerebral hemorrhage, is safe in clinical application and does not stimulate organs after being taken. By means of reasonable combination of the components, the curative effect is remarkably improved, the drug property is changed or alleviated, and toxic and side effects of the medicinal materials can be eliminated. The traditional Chinese medicine composition has short treatment cycle and remarkable curative effect. Clinical application studies indicate that the traditional Chinese medicine composition has an effective cure rate for cerebral hemorrhage of 91.7 percent and a total effective rate of 98.3 percent.
it is now recognized that there is a link between certain environmental exposures (occupational and extra-occupational) and reproductive pathologies. During pregnancy, environmental exposures are associated with an increased risk of spontaneous miscarriage, congenital malformations, certain adverse outcomes (fetal death in utero, intrauterine growth retardation, prematurity) and could also increase the risk of chronic disease in childhood and adulthood (hypothesis of developmental origins of health and disease), and have transgenerational effects. Intervention studies have shown efficacy in reducing exposures to certain chemicals, particularly by reducing exposure to cosmetics. In the scientific literature, a pre-conception visit is recommended to identify environmental exposures. In France, platforms are dedicated to the evaluation of environmental exposures in patients with fertility disorders and pregnancy-related pathologies and provide support for the implementation of targeted prevention actions.

The intervention is taken care of by the PREVENIR platforms. This care consists of a consultation carried out by an environmental health expert (midwife, environmental health engineer) from the PREVENIR platforms. This consultation is carried out through a protocolized interview already developed which allows the identification of exposure to risk factors on reproduction. During the interview, prevention messages targeted at the exposures identified during the interview are delivered.
<P>PROBLEM TO BE SOLVED: To provide a structured drug system that is useful for delivering a drug payload to a specific tissue or cell type.  <P>SOLUTION: The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can be used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
BACKGROUND: Intestinal metaplasia (IM) is classified into complete intestinal metaplasia (CIM) and incomplete intestinal metaplasia (IIM). Patients diagnosed with IIM face an elevated susceptibility to the development of gastric cancer, underscoring the critical need for early screening measures. In addition to the complexities associated with diagnosis, the exact mechanisms driving the progression of gastric cancer in IIM patients remain poorly understood. OLFM4 is overexpressed in several types of tumors, including colorectal, gastric, pancreatic, and ovarian cancers, and its expression has been associated with tumor progression.
METHODS: In this study, we used pathological sections from two clinical centers, biopsies of IM tissues, precancerous lesions of gastric cancer (PLGC) cell models, animal models, and organoids to explore the role of OLFM4 in IIM.
RESULTS: Our results show that OLFM4 expression is highly increased in IIM, with superior diagnostic accuracy of IIM when compared to CDX2 and MUC2. OLFM4, along with MYH9, was overexpressed in IM organoids and PLGC animal models. Furthermore, OLFM4, in combination with Myosin heavy chain 9 (MYH9), accelerated the ubiquitination of GSK3β and resulted in increased β-catenin levels through the Wnt signaling pathway, promoting the proliferation and invasion abilities of PLGC cells.
CONCLUSIONS: OLFM4 represents a novel biomarker for IIM and could be utilized as an important auxiliary means to delimit the key population for early gastric cancer screening. Finally, our study identifies cell signaling pathways involved in the progression of IM.
At present, surgery is the preferred modality for the treatment of HCC patients with radical cure and long-term survival. However, 70% to 80% of HCC is advanced, and only 15% to 30% of patients are able to undergo surgical resection. For unresectable HCC, transformation therapy is currently used, and the response rate can be effectively increased through the "TKI plus IO" or "TKI plus IO and local therapy" regimen. For locally advanced HCC (stage III-IV), HAIC or HAIC + systemic therapy is recommended. And the first-line treatment of advanced HCC, TKI (Lenvatinib, Donafenib) or IO combined TKI are recommended. For patients with potentially resectable HCC, there are currently few explorations, and more effective treatment options and evidence-based medical evidence are needed. Therefore, this study investigated the efficacy and safety of FOLFOX-HAIC combined with Lenvatinib and Envolizumab in the treatment of patients with potentially resectable HCC, and explored the relationship between biomarkers, prognostic factors and efficacy.
Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent. The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer precipitate. In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.
An Immediate denture is a complete or partial removable prosthesis that is fitted immediately after extraction or modification of teeth. The prosthesis replaces the missing/modified teeth and where required, the adjacent hard and soft tissues. It is constructed prior to the extraction of teeth and is used immediately to provide function and aesthetics which are lost as a result of tooth removal and avoid the embarrassment patients may have with living without teeth, while waiting for the tissues to heal prior to definitive tooth replacement.1 (See image 1) Some clinicians take impressions on the day of the extractions and fit the dentures a few days later. These dentures are fraught with challenges as the alveolar ridge begins to resorb soon after. Therefore an immediate denture is only truly an immediate denture when fitted on the day of the extractions.

The use of a removable prosthesis within the UK is currently around 19% of adults in the general population 2 and in spite of this decreasing trend, as patients retain their natural dentition into older age,2 there is still a need for prosthodontic replacement as teeth are lost as a result of caries, periodontal disease, tooth wear or trauma. 3,4,5 The provision of an immediate denture can be challenging and close co-operation between patient, technician, and clinician is required.
Intervention group participants met with an experienced sleep scientist to discuss and agree changes to their sleep and personal schedules. Discussions lasted 60-90 minutes, were informed by actigraphic sleep assessments from the baseline period, and aimed to increase TST by ≥1 hour/night. The structure and content of the "About Sleep", "Sleep Hygiene" and "Thoughts and Sleep" components of the online Sleepful application, a self-help sleep management programme. Advice was supported by the provision of self-help booklets addressing sleep hygiene and the management of pre-sleep cognitions which had been successfully trailed in an intervention for insomnia symptoms. Finally, to capitalize on the participant's motivation at recruitment, and optimize adherence, the newly agreed sleep schedule was written into an agreement which the participant was asked to sign, simulating a 'therapeutic contract'. Schedules were reviewed by telephone at the end of the first week and revised if required.
In accordance with the useful model, the cosmetic composition contains in weight %: lyophilized extract of snail mucus and lyophilized extract of snail eggs, while the quantity of the components is the following: lyophilized extract of snail mucus from 0.001 to 0.5, lyophilized extract of snail eggs from 0.001 to 7, argan oil from 0.10 to 10, anti-inflammatory agent from 0.01 to 0.50, humectantsfrom 1 to 10, alpha-hydroxy acid from 0.01 to 1, retinyl palmitate from 0.01-0.5, tocopheryl acetate from 0.1 - 2,0, D-panthenol from 0.1 to 5.0, preservative from 0.05 to 1.20, chelate compound from0,05 to 0,2, perfume composition from 0.0 to 0.7, thickener from 2 to 5, antioxidants from 0.01 to 1.00 and deionised water up to 100, and in some cases additionally contains a surfactant or regenerating additive and/or water/oil stabilizing composition and/or solvents of oil components. The composition of the useful model provides a surprisingly rapid effect. The effect of its use according to the purpose becomes evident between the 5-th and the 10-th day of the treatment of the skin areas. In accordance with the useful model, the cosmetic composition has a very quick and positive effect on acne and signs of acne, rosacea, age spots and freckles, wrinkles and frown lines, including "crow's feet", scars, stretch marks, dead skin cells that need exfoliation. The cosmetic composition retains the biological activity of the active substance for a long period of time. The enzymes contained in the cosmetic composition retain their conformational integrity and activity, respectively. This activity is controllable depending on the use of the composition according to the useful model. The shelf life of the composition according to the useful model is extended significantly and hence the possibilities for its storage, which does not require special conditions.
NEW MATERIAL:A compound expressed by the formula [R1 is H or methyl; R2 is mono- or polyethylene glycol residue expressed by (CH2CH2O)nH (n is 1-6)]. EXAMPLE:ML-236B diethylene glycol ester. USE:A remedy for hyperlipemia having high stability and excellent blood cholesterol reducing action. PREPARATION:ML-236B or monacolin K is reacted with mono- or polyethylene glycol in the presence of an inorganic acid, such as HCl or H2SO4, as a catalyst to afford the aimed compound expressed by the formula. The reaction is carried out by using a solvent, e.g. benzene or chloroform. The compound expressed by the formula is administered in a dose within the range of about 0.2-500mg per day for an adult by intravenous injection, intraoral administration, etc.
The purpose of the study was to access safety and accuracy of Hemopill and its receiver. Patients scheduled for endoscopy on the basis of suspected UGIB are generally eligible for inclusion into the trial. After patient screening, information and obtaining informed consent, a patient is enrolled into the trial. Shortly before the scheduled endoscopy is performed, the patient ingests a HemoPill acute. Endoscopy is performed as scheduled. Blood within the GI lumen is identified if present and pictures are taken. Pathologies, if found, are treated as per clinical standard. The HemoPill acute measurement regarding presence or absence of blood in the GI lumen is compared to observations made during endoscopy.
Group G will receive a 5ml preparation of normal saline 0.9% as placebo prior to commencement of general anaesthesia. At the start of wound closure, a stat dose of IV granisetron 1mg in 5ml preparation will be administered.
Placebo will be dispensed by the study team on Day 0 at the clinical visit at the study site. Participants will be given enough Placebo for the 7-day treatment phase, (eg. Days 2 to 8). Treatment is twice daily, am and pm, 12 h apart ± 2 h. Placebo tablets will be matched to the active treatment and will be administered orally for 7 days as follows: 4 tablets for the initial dose as soon as symptoms are present or the subject answers "yes" to "do you think you have a cold today" on the first day of dosing (eg. Day 2), and 2 tablets, either on the same day (eg Day 2) or the next day. Treatment will therefore be for a total of 7 days (consisting of an initial 4-tablet dose followed by thirteen 2-tablet doses). Treatment may occur within the home, on non-clinical study days.
NEW MATERIAL:A compound of formula I {A, B, Y and Z are together H or A and B and Y and Z together form single bond; n is an integer 1-3; X is formula II[R<2> is formula III (R<3> is H or lower alkyl; m is an integer 1-5), etc.; R<1> is H, lower alkyl or halogen] or formula IV (K and L are h or K and L together form single bond), etc.}. EXAMPLE:2-Palmitoylamino-2-ethyl-1,3-propanediol. USE:An antithrombotic agent having anti PAF action and antithrombin action. PREPARATION:A polyprenylcarboxylic acid of formula V or a reactive derivative thereof is amidated with an amine in a solvent, e.g. dioxane or tetrahydrofurna, to afford the aimed compound of formula I .
FIELD: medicine, pulmonology, pharmacy. SUBSTANCE: invention relates to treatment of acute bronchial asthma attack. Invention proposes composition containing formoterol or its pharmaceutically acceptable salt and budesonide. Invention relates also to method for treatment of acute asthma state wherein composition containing the first and the second active component as indicated above is administrated by inhalation. Method provides arresting bronchial asthma attack and elimination of adverse effects of treatment. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 24 cl
Systems and methods for aiding, supplementing, and/or increasing the monitoring capabilities of responsible persons over a supervised person are disclosed herein. In some implementations, the system includes one or more controlling persons, one or more supervising persons, a supervised person, and a cloud server. Each of the controlling persons and the supervising persons can have a personal electronic device. The supervised person can have a wearable electronic device. The electronic devices allow the controlling persons and the supervising persons to actively communicate with the cloud server to upload data related to the supervised person that is accessibly stored in the cloud server. In turn, the wearable device can include one or more sensors to measure and communicate various bioindicators to the cloud server. The system allows the controlling persons to monitor the health of, development of, and/or current control over the supervised person.
This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
During the process of wound healing, the stimulation of inflammatory factors often leads to abnormal proliferation of blood vessels and collagen, ultimately resulting in scar formation. To address this challenge, we fabricate a novel dermal extracellular matrix (DECM) hydrogel scaffold loaded with ginsenoside Rg3 (Rg3) using 3D printing technology. Mesoporous silica nanoparticles (MSNs) are introduced into the system to encase the Rg3 to control its release rate and enhance its bioavailability. We systematically evaluate the biological, physicochemical, and wound healing properties of this scaffold. In vitro studies demonstrate that the hydrogel exhibits excellent biocompatibility and solid-like rheological properties, ensuring its successful printing. In vivo studies reveal that the composite hydrogel scaffolds effectively accelerate wound healing and achieve scar-free wound healing within three weeks. Histological and immunohistochemical (IHC) analyses show that the composite hydrogel scaffolds reduce the inflammatory response and inhibit excessive collagen accumulation. These combined effects underscore the potential of our approach in effectively inhibiting scar formation.
Substantially pure interleukin-1 converting enzyme isoforms are disclosed. Pharmaceutical compositions comprising one or more interleukin-1 converting enzyme isoforms are disclosed. Nucleic acid molecules that encode interleukin-1 converting enzyme isoforms, recombinant expression vectors that comprise a nucleic acid sequence that encodes an interleukin-1 converting enzyme isoform, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode interleukin-1 converting enzyme isoforms are disclosed. Fragments of nucleic acid molecules with sequences encoding interleukin-1 converting enzyme isoform and oligonucleotide molecules that comprise a nucleotide sequence complimentary to fragment of a nucleotide sequence that encodes an interleukin-1 converting enzyme isoform are disclosed. Antibodies which bind to an epitope on interleukin-1 converting enzyme isoforms are disclosed. Methods of identifying inhibitors of ICE isoforms are disclosed.
The present disclosure belongs to the field of skin care products, and particularly discloses a polysaccharide composition with moisturizing, repairing and anti-aging functions. The polysaccharide composition includes Dendrobium ofﬁcinale Kimura et Migo polysaccharide, Prunus persica (L.) Batsch polysaccharide, Polygonatum odoratum (Mill. ) Druce polysaccharide and Glycyrrhiza uralensis Fisch. polysaccharide, wherein the ratio of the Dendrobium ofﬁcina/e Kimura et Migo polysaccharide to the Prunus persica (L.) Batsch polysaccharide to the Polygonatum odoratum (Mi/l.) Druce polysaccharide to the Glycyrrhiza ura/ensis Fisch. polysaccharide is 1: (0.3-0.6): (0.5-1): (0.8-1.2). The polysaccharide composition with moisturizing, repairing and anti-aging functions provided by the present disclosure includes the Dendrobium ofﬁcinale Kimura et Migo polysaccharide, the Prunus persica (L.) Batsch polysaccharide, the Polygonatum odoratum (Mi/l.) Druce polysaccharide and the Glycyrrhiza ura/ensis Fisch. polysaccharide; and the polysaccharide composition has a synergistic effect on expression of aquaporin, and can improve water transmission and/or wetting agent transmission in skin, prevent and/or treat diseases caused by skin barrier damage and prevent and/or treat sicca syndrome, thus achieving the effects of repairing mucosa and relieving skin dryness and aging.
The present invention relates to a Clofarabine freeze drying powder and the preparation method, which comprises Clofarabine and at least one biological acceptable excipient. Wight ratio of the Clofarabine and the excipient is from one to 10 till one to 50. The excipient is selected from one kind of mannitol and lactose. The optional choice is the mannitol. The preparation method is as following. The Clofarabine is melted with the injection water and the excipient is added. Followed by well mixing , filtration, packaging, adding stopper and loading in the plate. The freeze dryer is opened in advance. The platelayer is cooled with the heat conduction oil until temperature of the platelayer increases till minus 40 DEG Cto minus 50 DEG C. The Clofarabine solution packaged in the sterile silinbottle can be sent to the freeze dryer quickly.The box door is shut and the plate temperature is kept at minus 40 DEG Cto minus 50 DEG C and the box temperature is decreased. When the sample temperature reaches minus 40 DEG C, The plate cooling is stopped and the condenser is opened. At the same time  the product temperature is maintaineed by cooling for 3 hours. When the temperature of the condenser reaches minus 40 DEG,  the vacuum system is opened. After temperature holding, four steps of heating, sublimation, drying, plugging, box pressing and opening sealing can be started.
Participants with primary resistance to prior anti-PD-1/PD-L1 will receive abexinostat PO BID on days -7 to -4 of the lead-in period, and days 1-4, 8-11 of each treatment cycle and pembrolizumab over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The 17th Eilat Conference on New Antiepileptic Drugs and Devices took place in Madrid, Spain on May 5-8, 2024. As usual, the core part of the conference consisted of presentations on investigational drugs at various stages of development for epilepsy-related indications. Summaries of information on compounds in preclinical or early clinical development are included in an accompanying publication (Part I). In this article, we provide summaries for five compounds in more advanced clinical development, i.e. compounds for which some information on antiseizure activity in individuals with epilepsy is available. These investigational treatments include azetukalner (XEN1101), a potent, KV7.2/7.3-specific potassium channel opener in development for the treatment of focal seizures, generalized tonic-clonic seizures, and major depressive disorder; bexicaserin (LP352), a selective 5-HT2C receptor superagonist in development for the treatment of seizures associated with developmental and epileptic encephalopathies; radiprodil, a selective negative allosteric modulator of NR2B subunit-containing N-methyl-D-aspartate glutamate receptors, in development for the treatment of seizures and behavior manifestations associated with disorders caused by gain-of-function mutations in the GRIN1, -2A, -2B, or -2D genes; soticlestat (TAK-935), a selective inhibitor of cholesterol 24-hydroxylase in development for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome; and STK-001, an antisense oligonucleotide designed to upregulate Nav1.1 protein expression and improve outcomes in individuals with Dravet syndrome. The diversity in mechanisms of action of these agents illustrates different approaches being pursued in the discovery of novel treatments for seizures and epilepsy. For two of the compounds discussed in this report (azetukalner and soticlestat), clinical evidence of efficacy has already been obtained in a randomized placebo-controlled adjunctive-therapy trial. For the other compounds, adequately powered placebo-controlled efficacy trials have not been completed to date.